Canakinumab

• Description :

  Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin[1][2].

• Product Name Alternative :

  Ilaris; ACZ 885

• UNSPSC :

  12352203

• Target :

  Interleukin Related

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/canakinumab.html

• Purity :

  99.64

• Solubility :

  10 mM in DMSO

• Smiles :

  [Canakinumab]

• Molecular Weight :

  (145.5 kDa)

• References & Citations :

  [1]Dhimolea E. Canakinumab. MAbs. Epub 2010 Jan 15. |[2]Rondeau JM, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs. 2015;7 (6) :1151-60.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Launched

• CAS Number :

  [914613-48-2]